Activity of sitafloxacin against extracellular and intracellular Staphylococcus aureus in vitro and in vivo: Comparison with levofloxacin and moxifloxacin

Journal of Antibiotics

Volumn 65, Issue 5, 2012, Pages 229-236

  Shi, Gongming ^a   Chen, Xiangdong ^a   Wang, Hui ^a   Wang, Siwen ^a   Guo, Xin ^a   Zhang, Xulei ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

a mouse peritonitis model; bactericidal effect; RAW264.7 macrophages; sitafloxacin; Staphylococcus aureus

Indexed keywords

LEVOFLOXACIN; MOXIFLOXACIN; QUINOLONE; SITAFLOXACIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM CULTURE; BACTERIUM ISOLATE; BROTH DILUTION; COLONY FORMING UNIT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR BACTERIUM; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PERITONITIS; PHAGOCYTOSIS; PRIORITY JOURNAL; SINGLE DRUG DOSE; STAPHYLOCOCCUS AUREUS;

ANIMALS; ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; CELL LINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EXTRACELLULAR SPACE; FLUOROQUINOLONES; INTRACELLULAR SPACE; MICE; MICE, INBRED ICR; MICROBIAL SENSITIVITY TESTS; OFLOXACIN; PERITONITIS; QUINOLINES; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TIME FACTORS;

BACTERIA (MICROORGANISMS); MUS; STAPHYLOCOCCUS AUREUS;

EID: 84861647894     PISSN: 00218820     EISSN: 18811469     Source Type: Journal    
DOI: 10.1038/ja.2012.7     Document Type: Article

References (29)

1. Kuehnert, M. J. et al. Methicillin-resistant-Staphylococcusaureus hospitalizations, United States. Emerg. Infect. Dis. 11, 868-872 (2005).
2. Iyer, S. & Jones, D. H. Community-Acquired methicillin-resistant Staphylococcusaureus skin infection: A retrospective analysis of clinical presentation and treatment of a local outbreak. J. Am. Acad. Dermatol. 50, 854-858 (2004).
3. Ferrara, A. M. Treatment of hospital-Acquired pneumonia caused by methicillinresistant Staphylococcusaureus. Int. J. Antimicrob. Agents 30, 19-24 (2007).
4. Fowler, V. G. Jr. et al. Staphylococcusaureus endocarditis: A consequence of medical progress. JAMA 293, 3012-3021 (2005).
5. Jensen, A. G., Espersen, F., Skinhoj, P. & Frimodt-Moller, N. Bacteremic Staphylococcusaureus spondylitis. Arch. Intern. Med. 158, 509-517 (1998).
6. Pedersen, M., Beneld, T. L., Skinhoej, P. & Jensen, A. G. Haematogenous Staphylococcus aureus meningitis. A 10-year nationwide study of 96 consecutivecases. BMC Infect. Dis. 6, 49 (2006).
7. Chang, F. Y. et al. Staphylococcus aureus bacteremia: Recurrence and the impact of antibiotic treatment in a prospective multicenter study. Medicine (Baltimore) 82, 333-339 (2003).
8. Ciampolini, J. & Harding, K. G. Pathophysiology of chronic bacterial osteomyelitis. Why do antibiotics fail so often? Postgrad. Med. J. 76, 479-483 (2000).
9. Esen, M. et al. Mechanisms of Staphylococcusaureus induced apoptosis of human endothelial cells. Apoptosis 6, 431-439 (2001).
10. Gresham, H. D. et al. Survival of Staphylococcusaureus inside neutrophils contributes to infection. J.Immunol. 164, 3713-3722 (2000).
11. Van Bambeke, F., Barcia-Macay, M., Lemaire, S. & Tulkens, P. M. Cellular pharmacodynamics and pharmacokinetics of antibiotics: Current views and perspectives. Curr. Opin. Drug Discov. Dev. 9, 218-230 (2006).
12. Barcia-Macay, M., Seral, C., Mingeot-Leclercq, M. P., Tulkens, P. M. & VanBambeke, F. Pharmacodynamic evaluation of the intracellular activities of antibiotics against Staphylococcusaureus in a model of THP-1 macrophages. Antimicrob. Agents Chemother. 50, 841-851 (2006).
13. Sandberg, A., Hessler, J. H., Skov, R. L., Blom, J. & Frimodt-Moller, N. Intracellular activity of antibiotics against Staphylococcusaureus in a mouse peritonitis model. Antimicrob. Agents Chemother. 53, 1874-1883 (2009).
14. VanBambeke, F. et al. Cellular pharmacokinetics and pharmacodynamics of the glycopeptides antibiotic oritavancin (LY333328) in a model of J774 mouse macrophages. Antimicrob. Agents Chemother. 48, 2853-2860 (2004).
15. Vande Velde, S., Nguyen, H. A., Van Bambeke, F. & Tulkens, P. M. Contrasting effects of human THP-1 cell differentiation on levofloxacin and moxifloxacin intracellular accumulation and activity against Staphylococcusaureus and Listeria monocytogenes. J. Antimicrob. Chemother. 62, 518-521 (2008).
16. Keating, G. M. Sitafloxacin in bacterial infections. Drugs 71, 731-744 (2011).
17. Barcia-Macay, M., Seral, C., Mingeot-Leclercq, M- P. & Tulkens, P. M. Pharmacodynamic evaluation of the intracellular activities of antibiotics against Staphylococcusaureus in a model of THP-1 macrophages. Antimicrob. Agents Chemother. 50, 841-851 (2006).
18. Raschke, W. C., Baird, S., Ralph, P. & Nakoinz, I. Functional macrophage cell lines transformed by Abelson leukemia virus. Cell 15, 261-267 (1987).
19. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J. Immunol. Methods 65, 55-63 (1983).
20. Zhao, X. & Drlica, K. Restricting the selection of antibiotic-resistant mutant bacteria: Measurement and potential use of the mutant selection window. J. Infect. Dis. 185, 561-565 (2002).
21. Sitafloxacin European patent specification EP1277471B1.
22. Manish Kumar, T., Srikanth, G., Venkateshwar Rao, J. & Sambasiva Rao, K.R.S. Development and validation of HPLC-UV method for the estimation of Levofloxacin in human plasma. Int. J. Pharm. Pharm. Sci. 3, 247-250 (2011).
23. Lismond, A. & Tulkens, P. M. Cooperation between prokaryotic (Lde) and eukaryotic (MRP) efflux Transportersin J774 macrophages infected with Listeria monocytogenes: Studies with Ciprofloxacin and Moxifloxacin. Antimicrob. Agents Chemother. 52, 3040-3046 (2008).
24. Tomioka, H., Saito, H., Sato, K. & Yoneyama, T. Therapeutic efficacy of liposome encapsulated kanamycin against mycobacterium intracellular infection induced in mice. Am. Rev. Respir. Dis. 144, 575-9 (1991).
25. Barcia-Macay, M., Lemaire, S., Mingeot-Leclercq, M. P., Tulkens, P. M. & Van Bambeke, F. Evaluation of the extracellular and intracellular activities (human THP-1 macrophages) of telavancin versus vancomycin against methicillin-susceptible, methicillin-resistant, vancomycin-intermediate and vancomycin-resistant Staphylococcusaureus. J. Antimicrob. Chemother. 58, 1177-1184 (2006).
26. Zhao, X. & Drlica, K. Restricting the selection of antibiotic-resistant mutants: A general strategy derived from fluoroquinolone studies. Clin. Infect. Dis. 33(Suppl 3), S147-156 (2001).
27. Baudoux, P. et al. Activity of quinupristin/ dalfopristin against extracellular and intracellular Staphylococcusaureus with various resistance phenotypes. J. Antimicrob. Chemother. 65, 1228-1236 (2010).
28. Lemaire, S. et al. Activities of ceftobiprole and other cephalosporins against extracellular and intracellular (THP-1macrophages and keratinocytes) forms of methicillinsusceptible and methicillin-resistant Staphylococcusaureus. Antimicrob. Agents. Chemother. 53, 2289-2297 (2009).
29. Motulsky, H. J. Analyzing Data with GraphPad Prism (GraphPad Software Inc., San Diego, CA, 2010).